- Strength in shares of Ariad Pharmaceuticals (ARIA +8.9%) has held up well throughout the session.
- From the JPMorgan note which sparked the rally: "The majority of docs we surveyed who have used Iclusig do not expect their use to change over the next 6-12 months [and] somewhat surprisingly, there were more docs who expect to increase their use of the drug vs. docs who expect use to decrease."
- As noted earlier, this would seem to suggest that investor concern over a recent FDA drug safety communication (see here and here) may be overblown.
- As for comparisons between Iclusig and Novartis' (NVS +1.4%) Tasigna, JPM says "only 4% of docs view Iclusig’s safety profile as 'significantly worse' than Tasigna" (52% of Iclusig-prescribing docs characterize the drug's safety profile is "moderately worse").
Most doctors surveyed plan no change to Iclusig prescriptions: JPMorgan
Oct 17 2013, 14:06 ET